Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Citation Information: J Clin Invest. 2011;121(9):3375-3383. https://doi.org/10.1172/JCI57158.
Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Published September 1, 2011
Citation Information: J Clin Invest. 2011;121(9):3375-3383. https://doi.org/10.1172/JCI57158.
Abstract
The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
Authors
Simon A. Jones, Jürgen Scheller, Stefan Rose-John
Full Text PDF | Download (460.19 KB)
Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)